Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2025 | $21.00 → $26.00 | Neutral → Overweight | Piper Sandler |
| 12/12/2024 | $25.00 → $24.00 | Buy → Hold | Deutsche Bank |
| 9/24/2024 | $27.00 | Buy | Jefferies |
| 9/24/2024 | $24.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 5/28/2024 | $21.00 | Neutral | Citigroup |
| 4/11/2024 | $18.00 | Underperform | Bernstein |
| 4/3/2024 | Mkt Perform | William Blair | |
| 3/1/2024 | $20.00 | Neutral | Goldman |
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously
Deutsche Bank downgraded Kenvue from Buy to Hold and set a new price target of $24.00 from $25.00 previously
Jefferies initiated coverage of Kenvue with a rating of Buy and set a new price target of $27.00
Kenvue Inc. (NYSE:KVUE) today announced Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 19, 2025, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-bac
Q4 Net Sales Decreased 0.1% to $3.7 Billion; Organic Sales1 Grew 1.7% Q4 Diluted EPS was $0.15; Adjusted Diluted EPS1 was $0.26 FY'24 Net Sales Increased 0.1% to $15.5 Billion; Organic Sales1 Grew 1.5% FY'24 Gross Profit Margin Improved 200 Basis Points and Our Vue Forward Savings Supported Increased Marketing Investment to Fuel Growth FY'24 Diluted EPS was $0.54; Adjusted Diluted EPS1 was $1.14 Provides Outlook for FY'25 Kenvue Inc. (NYSE:KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. "We delivered on our 2024 profit commitments despite headwinds that resulted in softer than expected sales growth and we
Company Confirms Receipt of Director Nominees from Starboard Value No Shareholder Action Required at This Time Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today issued the following statement in response to Starboard Value's ("Starboard") submission of four nominees to stand for election to the Kenvue Board of Directors at Kenvue's 2025 Annual Meeting of Shareholders: The Kenvue Board and management team are committed to acting in the best interests of Kenvue and our shareholders. We engage regularly with our shareholders and are open to constructive dialogue with and suggestions from Kenvue shareholders. We note that members o
SCHEDULE 13G - Kenvue Inc. (0001944048) (Subject)
8-K - Kenvue Inc. (0001944048) (Filer)
PREC14A - Kenvue Inc. (0001944048) (Subject)
Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa
Q4 Net Sales Decreased 0.1% to $3.7 Billion; Organic Sales1 Grew 1.7% Q4 Diluted EPS was $0.15; Adjusted Diluted EPS1 was $0.26 FY'24 Net Sales Increased 0.1% to $15.5 Billion; Organic Sales1 Grew 1.5% FY'24 Gross Profit Margin Improved 200 Basis Points and Our Vue Forward Savings Supported Increased Marketing Investment to Fuel Growth FY'24 Diluted EPS was $0.54; Adjusted Diluted EPS1 was $1.14 Provides Outlook for FY'25 Kenvue Inc. (NYSE:KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. "We delivered on our 2024 profit commitments despite headwinds that resulted in softer than expected sales growth and we
Company Confirms Receipt of Director Nominees from Starboard Value No Shareholder Action Required at This Time Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today issued the following statement in response to Starboard Value's ("Starboard") submission of four nominees to stand for election to the Kenvue Board of Directors at Kenvue's 2025 Annual Meeting of Shareholders: The Kenvue Board and management team are committed to acting in the best interests of Kenvue and our shareholders. We engage regularly with our shareholders and are open to constructive dialogue with and suggestions from Kenvue shareholders. We note that members o
Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2024 financial results before market open on February 6, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)